WilliamFrankNovotnyMD

PubMed

• 71 citations
  Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metas...
  David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore 3rd, Jacques Gaudreault, Lis...> ;Journal of Clinical Oncology. 2023 May 1
• 142 citations
  Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of-Overexpressing Metastatic Breast Cancer.
  Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Bu...> ;Journal of Clinical Oncology. 2023 Mar 20
• 1 citations
  A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
  Bilal Tariq, Ying C Ou, Jennifer C Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman, Ste...> ;Leukemia & Lymphoma. 2023 Feb 1
• 20 citations
  Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
  Gavin Cull, Jan A Burger, Stephen Opat, David Gottlieb, Emma Verner, Judith Trotman, Paula Marlton, Javier Munoz, Patrick Johnston, David Simpson, Jennifer C Stern, Ra...> ;British Journal of Haematology. 2022 Mar 1
• 37 citations
  Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
  Constantine S. Tam, Meletios A. Dimopoulos, Ramón García-Sanz, Judith Trotman, Stephen Opat, Andrew W. Roberts, Roger G. Owen, Yuqin Song, Wei Xu, Jun Zhu, Jianyong Li...> ;Blood Advances. 2021 Nov 1
• 19 citations
  Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma.
  Haiyan Yang, Bing Xiang, Yuqin Song, Huilai Zhang, Wei-Li Zhao, Dehui Zou, Fangfang Lv, Wei Guo, Caixia Li, Ziwen Tan, Yang Liu, Lina Fu, Haiyi Guo, William Novotny, J...> ;Blood Advances. 2021 Oct 12
• 16 citations
  Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
  Ying C. Ou, Zhiyu Tang, William Novotny, Aileen Cohen, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman> ;Leukemia & Lymphoma. 2021 Jun 23
• 52 citations
  Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
  Constantine S. Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz, Tycel Phillips, Won Seog Kim, Simon Rule, Siminder Kaur Atwal, Rachel Wei, William Novotny, ...> ;Blood Advances. 2021 Jun 22
• 12 citations
  Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP
  Ying C. Ou, Zhiyu Tang, William Novotny, Manal Tawashi, Ta-Kai Li, Hugh A Coleman, Srikumar Sahasranaman> ;British Journal of Clinical Pharmacology. 2021 Jul 1
• 12 citations
  A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
  Martin Dreyling, Constantine S. Tam, Michael Wang, Stephen D. Smith, Marco Ladetto, Huiqiang Huang, William Novotny, Melannie Co, Alfredo Romano, Eric Holmgren, Jane H...> ;Future Oncology. 2021 Jan 1
• 67 citations
  Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
  Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F Seymour, Siminder ...> ;Blood. 2020 Oct 29
• 112 citations
  Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
  Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, ...> ;Clinical Cancer Research. 2020 May 27
• 81 citations
  Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
  Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, Willi...> ;Journal of Hematology & Oncology. 2020 May 11
• 5 citations
  No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
  Song Mu, Borje Darpo, Zhiyu Tang, William Novotny, Manal Tawashi, Hongqi Xue, Michael Willett, Leo Lin, Sri Sahasranaman, Ying C. Ou> ;Clinical and Translational Science. 2020 Mar 7
• 13 citations
  A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
  Ying C. Ou, Richard A. Preston, Thomas Marbury, Zhiyu Tang, William Novotny, Manal Tawashi, Ta Kai Li, Srikumar Sahasranaman> ;Leukemia & Lymphoma. 2020 Feb 7
• 90 citations
  Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
  Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Liudi Yang, Rebecca Elst...> ;Leukemia. 2020 Feb 1
• 28 citations
  Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
  Song Mu, Zhiyu Tang, William Novotny, Manal Tawashi, Ta-Kai Li, Ying Ou, Srikumar Sahasranaman> ;Cancer Chemotherapy and Pharmacology. 2020 Feb 1
• 402 citations
  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
  Pedram Razavi, Bob T. Li, David N Brown, Byoungsok Jung, Earl Hubbell, Ronglai Shen, Wassim Abida, Krishna Juluru, Ino de Bruijn, Chenlu Hou, Oliver Venn, Raymond S. L...> ;Nature Medicine. 2019 Nov 25
• 230 citations
  Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
  Constantine S. Tam, Judith Trotman, Stephen Opat, Jan A. Burger, Gavin Cull, David Gottlieb, Rosemary Harrup, Patrick B. Johnston, Paula Marlton, Javier Munoz, John F....> ;Blood. 2019 Sep 12
• 30 citations
  A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
  Constantine S. Tam, Véronique Leblond, William Novotny, Roger G. Owen, Alessandra Tedeschi, Siminder Kaur Atwal, Aileen Cohen, Jane Huang, Christian Buske> ;Future Oncology. 2018 Jun 5
• 37 citations
  Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
  Yang Pan, R. Xu, Matthew Peach, Huang Cp, Daniel Branstetter, William Novotny, Roy S. Herbst, Eckhardt Sg, Pamela M. Holland> ;British Journal of Cancer. 2011 Dec 6
• Quantitative gene expression in primary and highest Gleason pattern cancer specimens identifies genes associated with clinical recurrence and prostate cancer-specific ...
  Klein EA, Falzarano SM, Maddala T, Lee M, Pelham RJ, Novotny WF, Shak S, Magi-Galluzzi C> ;J. Clin. Oncol.. 2011-05-20
• Use of TMPRSS2-ERGgene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.
  Falzarano SM, Magi-Galluzzi C, Novotny WF, Maddala T, Cherbavaz DB, Millward C, Klein EA> ;J. Clin. Oncol.. 2011-05-20
• Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC).
  Campbell S, Knezevic D, Maddala T, Novotny WF, Zhou M, Aydin H, Elson P, Parodi L, Goddard AD, Rini BI> ;J. Clin. Oncol.. 2011-03-01
• Use of quantitative gene expression in primary and highest Gleason pattern cancers to identify genes associated with clinical recurrence after radical prostatectomy.
  Klein EA, Falzarano SM, Maddala T, Millward C, Novotny WF, Pelham RJ, Magi-Galluzzi C> ;J. Clin. Oncol.. 2011-03-01
• Join now to see all